Trenbolone
EmergingVeterinary cattle implant repurposed as the most potent mainstream AAS in bodybuilding. | AAS · Oil injectable
Aliases (7)
▸ Vial inspection & sterile draw AAS oil
AAS oil arrives pre-suspended in carrier oil — no BAC water needed. Inspect for clarity, color, and crashed compound (cold storage can crystallize). Warm vial in palm or under hot tap before draw.
- 1 Wipe vial stopper with isopropyl alcohol.
- 2 Warm vial 30-60s in palm if oil is cold/cloudy.
- 3 Draw with 18g needle into 22-25g pin barrel for IM, or 27-29g for sub-Q.
- 4 Tap out air bubbles, expel a small drop, then inject at chosen site.
▸ Cycle structure & PCT AAS
Ramp dose over week 1, hold steady through cycle weeks. Track baseline labs (TT/FT/E2/SHBG/HCT/lipids/LFTs) at week 0; recheck at week 4 and end-of-cycle.
On the last dose, the ester clears over its half-life window (acetate = est. ~7 days). PCT begins after the active compound has cleared.
Standard PCT is enclomiphene 12.5-25 mg/day or clomid 50/50/25/25 over 4 weeks (or nolvadex 20/20/10/10). HCG bridge optional during cycle to preserve testicular volume + faster restart. Bloodwork at PCT week 4 + 8 to confirm HPG axis recovery (LH, FSH, TT back to baseline).
▸ Overview TL;DR
Veterinary cattle implant repurposed as the most potent mainstream AAS in bodybuilding. Dramatic body-composition effects come bundled with severe HPG suppression, glucocorticoid-driven cardiovascular damage, progestogenic gynecomastia risk, and a notorious psychiatric profile ("tren rage" — insomnia, aggression, anxiety, sexual dysfunction). Categorical SKIP for a 20yo brain-priority athlete.
▸ Mechanism of action
Trenbolone is a 19-nortestosterone derivative (no aromatase substrate, but progestin-like) originally developed as Finaplix / Revalor cattle implants to increase feed conversion in beef cattle.
- Androgen receptor (AR) binding affinity ~5× testosterone — among the highest of any AAS. Drives extreme protein synthesis, lipolysis, satellite-cell recruitment.
- Glucocorticoid receptor (GR) agonist — unusual for an AAS. This contributes to lipolysis but also drives cardiovascular damage, anxiety, sleep disruption, and connective-tissue catabolism. The GR activity is a major reason Tren "feels different" from testosterone.
- Progestogenic activity — binds progesterone receptor, can drive prolactin elevation, gynecomastia, sexual dysfunction. Aromatase inhibitors (the standard estrogen-control tool) do not address this; cabergoline / dostinex is often added.
- Non-aromatizable — does not convert to estradiol. This sounds advantageous but removes estrogen's cardioprotective role (HDL, vascular endothelium), worsening lipid profile.
- 5α-reductase resistant — does not convert to DHT, but the parent compound is itself extraordinarily androgenic in tissues.
- HPG suppression severity: among the most severe of any AAS. LH/FSH crash within days; recovery post-cycle takes months and is not guaranteed at high cumulative dose.
▸ Pharmacokinetics No data
▸Research indications5 use cases
Androgen receptor (AR) binding affinity ~5× testosterone
Most effectiveamong the highest of any AAS. Drives extreme protein synthesis, lipolysis, satellite-cell recruitment.
Glucocorticoid receptor (GR) agonist
Effectiveunusual for an AAS. This contributes to lipolysis but also drives cardiovascular damage, anxiety, sleep disruption, and connective-tissue…
Progestogenic activity
Effectivebinds progesterone receptor, can drive prolactin elevation, gynecomastia, sexual dysfunction. Aromatase inhibitors (the standard estrogen…
Non-aromatizable
Moderatedoes not convert to estradiol. This sounds advantageous but removes estrogen's cardioprotective role (HDL, vascular endothelium), worseni…
5α-reductase resistant
Moderatedoes not convert to DHT, but the parent compound is itself extraordinarily androgenic in tissues.
▸Quality indicators5 checks
▸ What to expect Generic
- 1Week 1-2Frontload phase. Strength gains start; appetite up.
- 2Week 3-4Visible muscle fullness and recovery acceleration.
- 3Week 5-8Peak performance window. Monitor blood pressure + libido.
- 4Post-cyclePCT week 1-4. Bloodwork at week 6 post-cycle.
▸ Side effects + safety
- Common (>10% users): Insomnia, night sweats, mood lability, irritability, elevated resting HR, elevated BP, sexual dysfunction (mid-cycle ED), anxiety, decreased cardio capacity, severe HPG suppression (universal).
- Less common (1-10%): Gynecomastia (progestogenic, not estrogen-mediated — AI does not help, cabergoline may), aggression incidents, panic-attack-like episodes, gross sleep architecture disruption, kidney function decline, hair-loss acceleration in genetically predisposed users, severe acne.
- Rare-serious (<1% but worth knowing): Acute kidney injury, cardiac event (MI, arrhythmia), psychotic episode, suicidal ideation, persistent post-cycle hypogonadism (failure to recover endogenous T after multiple cycles), tren cough (acute pulmonary reaction during injection — bronchospasm, taste of metal, cough fit lasting minutes; usually self-limited but distressing), rhabdomyolysis.
- Specific watch periods:
- Lifetime: brain development is incomplete until ~25; introducing a high-AR + high-GR compound during this window has unstudied long-term consequences for HPA-axis setpoint, mood circuitry, and androgen-receptor sensitization.
- First 4 weeks: psychiatric side effects (sleep, mood) often peak.
- Mid-cycle through PCT: sexual dysfunction, lipid damage, kidney/cardiac surveillance.
- 6-12 months post-cycle: ASIH may persist; some users never fully recover.
▸Interactions3 compounds
- All AASAvoidstacking compounds the cardiovascular and HPG damage non-linearly.
- Stimulants (modafinil, amphetamines, high-dose caffeine)Avoidadditive cardiovascular load; Tren already raises HR/BP significantly.
- SSRIs / antidepressantsAvoidinteracts unpredictably with the AAS-mood axis.